We report the genotyping analysis of Toxoplasma gondii isolates in samples collected from 88 immunocompromised patients, along with clinical and epidemiological data. Most of these samples were collected in France during the current decade by the Toxoplasma Biological Resource Center. Lack of specific anti-Toxoplasma treatment, pulmonary toxoplasmosis, and involvement of multiple organs were the 3 main risk factors associated with death for this patient group. Genotyping results with 6 microsatellite markers showed that type II isolates were predominant among patients who acquired toxoplasmic infection in Europe. Non-type II isolates included 13 different genotypes and were mainly collected from patients who acquired toxoplasmosis outside Europe. Type III was the second most common genotype recovered from patients, whereas type I was rare in our population. Three nonarchetypal genotypes were repeatedly recovered from different patients who acquired the infection in sub-Saharan Africa (genotypes Africa 1 and Africa 2) and in the French West Indies (genotype Caribbean 1). The distribution of genotypes (type II vs. non-type II) was not significantly different when patients were stratified by underlying cause of immunosuppression, site of infection, or outcome. We conclude that in immunocompromised patients, host factors are much more involved than parasite factors in patients' resistance or susceptibility to toxoplasmosis.
that may induce life-threatening disease. In patients with AIDS, those with hematological malignancies, and those who undergo hematopoietic stem cell transplantation (HSCT), toxoplasmosis mainly occurs after reactivation of latent infection, rarely during a primary infection. In patients who have undergone solidorgan transplantation, T. gondii is mainly transmitted via a graft from a donor who is seropositive for Toxoplasma to a recipient who is seronegative for Toxoplasma. Toxoplasmic encephalitis is considered to be the most frequent clinical presentation, especially in patients with AIDS [4] , and the lung is the second most common site of disease due to T. gondii in immunocompromised patients [5] . The involvement of other organs, such as the eye, heart, peritoneum, liver, spleen, kidney, muscle, and bone marrow have also been described, albeit infrequently [6] . In fact, multiple-organ involvement is rarely found clinically but is a frequent finding at autopsy [7] .
Toxoplasmic encephalitis is one of the major opportunistic infections that occur in patients with AIDS. Although its incidence has been reduced by three-quarters as a result of highly active antiretroviral therapy (HAART) and primary prophylaxis [8] , toxoplasmic encephalitis remains the most prevalent cause of neurological opportunistic infection in HIV-infected patients in Europe [9] . In France, toxoplasmic encephalitis was the fourth most frequent AIDS-indicative disease in 2005-2006 [10] . Toxoplasmosis-associated deaths have dramatically decreased among HIV-infected persons in the United States, reflecting the effectiveness of anti-Toxoplasma treatment and primary prophylaxis, as well as HAART [11] . However, because toxoplasmic encephalitis is associated with a high probability of early death, survival analysis shows that the occurrence of toxoplasmic encephalitis remains associated with a poor prognosis in the natural history of HIV-infected persons, even in the era of HAART [9] .
In contrast to patients with AIDS, toxoplasmosis is considered to be a rare opportunistic infection in patients who are immunosuppressed because of other causes, such as recipients of HSCT or solid-organ transplants [12, 13] , and in patients with lymphoproliferative or myelopoietic malignancies [6] . The highest incidences of toxoplasmosis are observed in patients who have undergone allogeneic HSCT and heart transplantation [14, 15] . In patients whose immunosuppression is not caused by HIV infection, toxoplasmosis is considered to have a poor prognosis [12] , and starting appropriate anti-Toxoplasma therapy as soon as possible is considered to be the main factor involved in survival [16] . Among heart transplant recipients, this disease and disseminated aspergillosis are associated with the highest mortality rates attributable to an infectious complication [15] .
During the past decade, on the basis of a limited sample of strains from domestic animals and humans from North America and western Europe, T. gondii was considered to have a clonal population structure and low genetic diversity, with Ͼ95% of strains belonging to 3 clonal lineages, which were named types I, II, and III [17] . Recent studies that used multiple markers and collected samples from Brazil and French Guiana [3, 18 -20] showed that, at least in the tropical part of South America, Toxoplasma strains show genetic diversity that is absent in strains from North America and Europe. In North America, the clonal types predominate [20] , but recent works suggest greater genetic diversity than was initially recognized [21] [22] [23] . In Europe, mainly in France, various studies conducted in animals and humans showed a tremendous predominance (Ͼ95%) of only 1 genotype, type II [24 -27] . Few data concerning the genetic diversity and population structure of this parasite are available for Africa [28, 29] and Asia [30, 31] , where 75% of the human population currently lives. The influence of genotype on the clinical presentation or outcome of the disease is poorly reported for immunocompromised patients [32] [33] [34] .
The Toxoplasma Biological Resource Center was created in 2003 in France. To date, this network of French parasitologists has collected 462 Toxoplasma isolates from patients with toxoplasmosis, together with clinical and epidemiological data for these patients. All these isolates have been genotyped with microsatellite markers. We report the genotyping analysis of T. gondii in samples collected from 88 immunocompromised patients-52 patients with AIDS and 36 patients whose immunosuppression was not due to HIV infection-and the correlation of genotypes with clinical findings. Most of these samples were collected in France during the current decade by the Toxoplasma Biological Resource Center.
MATERIALS AND METHODS

Patients.
Epidemiological and clinical data for the 88 immunocompromised patients are reported in table 1. The serological findings (data not shown) permitted us to know the geographical origin of toxoplasmic infection (i.e., the country of residence during the infection) for 6 patients with recent primary infection . For 72 patients with reactivated infection, we assumed that toxoplasmic infection occurred in the country from which the patients originated. For 9 patients, the geographical origin of infection was unknown because of insufficient data or because of Toxoplasma transmission via the graft in patients who underwent solid-organ transplantation. For 1 patient, despite the absence of serological data, we assumed that toxoplasmic infection occurred in France because this case involved a 6-year-old child with no history of travel outside France. Infection was presumed to have originated in Europe for 52 patients (48 in France, 2 in Portugal, 1 in Germany, and 1 in Austria) and to have originated outside Europe for 27 patients (17 in sub-Saharan Africa, 4 in the French West Indies, 3 in South America, 1 in Central America, 1 in Maghreb, and 1 on Reunion Island).
The underlying causes of immunosuppression were as follows: 52 patients had AIDS; of the 36 patients negative for HIV infection, 27 had undergone transplantation (12 received bone marrow transplants, 4 received cord blood cell transplants, and 11 received solid-organ transplants), 4 had lymphoma, 3 had leukemia, 1 had IgA nephropathy (i.e., Berger disease), and 1 had iatrogenous aplasia. All but 1 of the patients were adults.
Data on the clinical features of toxoplasmosis were available for all 88 patients. The most frequent site of infection was the brain (49 patients with toxoplasmic encephalitis), followed by the lung (39 patients with pulmonary toxoplasmosis), bone marrow (7 patients with medullar toxoplasmosis), peritoneum (4 patients with peritoneal toxoplasmosis), and heart (3 patients with myocardial toxoplasmosis). Other locations (e.g., the liver, kidney, pancreas, eye, lymph node, and spinal cord) occurred rarely. Toxoplasmosis involved a single organ in 67 patients and 2 noncontiguous organs (hereafter, "multiple organ") in 21 patients.
For 76 of 88 patients, we could determine whether specific anti-Toxoplasma drug therapy was given. The outcome was available for 84 patients. A total of 45 patients died; for 35 of these patients, death was caused by toxoplasmosis. Of the 35 patients who died of toxoplasmosis, 9 did not receive specific anti-Toxoplasma therapy because of the rapid, fatal progression of the disease.
Toxoplasma isolates and DNA extracts. Genotyping analysis. Strain typing was performed by using the length polymorphism of 6 microsatellite markers in a modified multiplex assay. Elsewhere, we described a multiplex polymerase chain reaction (PCR) for typing strains of T. gondii by use of 5 microsatellite markers (TUB2, W35, TgM-A, B18, and B17) [35] . For this study, we added a sixth microsatellite marker to the multiplex assay, M33, which is located on chromosome IV. The primer sequences of the microsatellite marker M33 were described elsewhere [36] . For this modified multiplex assay, the forward primer of M33 was 5'-end labeled with 2,7',8'-benzo-5'-fluoro-2',4,7-trichloro-5-carboxyfluorescein (NED 
RESULTS
Clinical and epidemiological data. As shown in table 2, toxoplasmic infection acquired outside Europe was observed significantly more frequently in patients with AIDS than in patients whose immunosuppression was not caused by HIV infection. Our study found a significantly higher rate of cerebral localization in patients with AIDS than in patients whose immunosuppression was not caused by HIV infection, whereas pulmonary localization was significantly more common in patients whose immunosuppression was not caused by HIV infection than in LGE Inguinal lymphadenopathy 3 months after discontinuation of secondary prophylaxis and 21 months after toxoplasmic encephalitis (see [33] ). patients with AIDS . There was no statistical difference between patients with AIDS and patients whose immunosuppression was not caused by HIV infection with respect to the occurrence of single or multiple-organ localization. These results were unchanged when adjusted for the geographical origin of infection. Our results in table 3 suggest that the prognosis of toxoplasmosis (death due to toxoplasmosis vs. survival) in immunocompromised patients was significantly linked to the underlying cause of immunosuppression, site of infection, and the receipt of specific antiToxoplasma treatment. Patients with AIDS were less likely to die than those whose immunosuppression was not due to HIV infection. Patients whose infection was cerebral had a better outcome than those whose infection was noncerebral, whereas pulmonary involvement was more frequently associated with death than was nonpulmonary localization. Patients with multiple-organ involvement had a worse prognosis than those with single-organ localization. These results were unchanged by multivariate logistic regression analysis, though it is worth noting that the rate of death among patients whose immunosuppression was not caused by HIV infection and in patients with multiple organ involvement reached borderline statistical significance when adjusted for the geographical origin of infection (P ϭ .054). Patients who did not receive specific anti-Toxoplasma therapy were more likely to die than those who received it. 
Genotyping analysis.
Genotyping results for the 88 isolates are reported in table 1. By use of 6 microsatellite markers, we identified the 14 different genotypes listed in table 4. One genotype, type II, was predominant; it was observed in 54 isolates (61.4%) . Non-type II strains accounted for 34 isolates (38.6%) and included the 13 remaining genotypes. Type III was the second most common genotype; infection due to isolates of this type was acquired in France for 6 patients, sub-Saharan Africa for 3 patients, and French Guiana for 1 patient. Type I isolates were recovered from 2 patients, including 1 who acquired toxoplasmosis in Uruguay. Three genotypes (Africa 1, Africa 2, and Caribbean 1), which are different from the archetypal genotypes I, II, and III, were recovered from several patients. The most common nonarchetypal genotype, Africa 1, was recovered from 9 patients: 6 who had a reactivated toxoplasmic infection and came from sub-Saharan African countries, 2 who had a primary infection acquired in Guinea and Senegal, respectively, and 1 who underwent renal transplantation that involved Toxoplasma transmission from the graft (donor of unknown origin). The Africa 2 genotype was recovered from 2 patients from Cameroon and Senegal, respectively, whereas the Caribbean 1 genotype was recovered from 3 patients from 2 islands in the French West Indies (Guadeloupe and Martinique). The 8 remaining genotypes, named Unique 1-8, were recovered from 1 patient each.
Correlation between genotypes and toxoplasmosis. As shown in table 5, the genotype of Toxoplasma strains was strongly linked to the presumed geographical origin of infection. Type II strain were more commonly recovered from patients with infections acquired in Europe than from those who acquired their infections outside Europe, and consequently nontype II strains were more commonly recovered from patients with infections acquired outside Europe than from those who acquired their infections in Europe (P Ͻ .001). Type II strains were predominant, regardless of the underlying cause of immunosuppression, site of infection, or outcome. There was no statistical difference between the rate at which type II strains and non-type II strains were recovered from patients with AIDS and patients whose immunosuppression was not caused by HIV infection; similarly, there was no statistical difference in this regard between patients with cerebral toxoplasmosis and those with noncerebral toxoplasmosis, between patients with pulmonary toxoplasmosis and those with nonpulmonary toxoplasmosis, between patients with a single site of infection and those with multiple organ localizations, or between patients with toxoplasmosis who died of toxoplasmosis and those who survived. These results were unchanged when adjusted for the geographical origin of infection. There was no statistical difference between the median CD4 ϩ cell count of patients with AIDS who were infected by type II strains and those infected by non-type II strains (24 vs. 35 cells/L, respectively).
DISCUSSION
Of 52 patients with AIDS, 39 (75.0%) had toxoplasmosis with cerebral involvement, whereas 16 (30.8%) had toxoplasmosis with pulmonary involvement. This confirms the predominance of toxoplasmic encephalitis in patients with AIDS [4] , but also underscores the fact that pulmonary toxoplasmosis is relatively common. Of 36 patients whose immunosuppression was not due to HIV infection, 23 (63.9%) had toxoplasmosis with pul- Table 4 . Allelic combinations for the 14 genotypes identified in isolates obtained from 88 immunocompromised patients with toxoplasmosis. monary involvement, whereas 10 (27.8%) had toxoplasmosis with cerebral involvement. These results were unexpected because studies and reviews from the past decade or earlier reported the brain as the main site of the disease in patients who have undergone HSCT [12, 16] and in patients with cancer [6] . The higher rate of pulmonary toxoplasmosis observed in our study is likely the consequence of the general accessibility and optimization of more sensitive diagnostic procedures in the current decade, such as PCR techniques, especially for bronchoalveolar lavage fluid samples. The number of organs involved (1 vs. 2) did not differ significantly between patients with AIDS and patients whose immunosuppression was not caused by HIV infection. Patients who acquired Toxoplasma infection outside Europe were predominantly persons with AIDS. This reflects the geographical and ethnic specificity of HIV epidemiology in France. In 2006, the median rate of positive HIV test results per million inhabitants was 178 in France but this rate was considerably higher in the 3 French overseas departments of America: 2077 in French Guiana, 861 in Guadeloupe, and 409 in Martinique [10] . Moreover, nearly 30% of newly diagnosed HIV infections in France occur among the migrant population from sub-Saharan African countries [10] . In our study, of the 46 patients with AIDS who also had reactivated toxoplasmosis, 23 originated from areas outside Europe, including 15 from sub-Saharan African countries, and 6 from French overseas departments.
The most important factors influencing outcome were the receipt of specific anti-Toxoplasma therapy, the site of infection, and the number of organs involved. No receipt of specific treatment, pulmonary toxoplasmosis, and the involvement of 2 noncontiguous organs (i.e., disseminated toxoplasmosis) were the risk factors associated with the worst prognosis, which is in accordance with other published data [16, 37] . All 9 patients who did not receive specific treatment died of toxoplasmosis, and 6 of them had multiple-organ involvement. Of the 18 patients who died of toxoplasmosis despite receiving specific therapy, 15 had pulmonary involvement, which shows that the lung is frequently involved in fatal cases of toxoplasmosis. The worse outcome observed for patients whose immunosuppression was not caused by HIV infection is explained by the increased frequency of pulmonary toxoplasmosis in these patients, compared with persons with AIDS, who predominantly had cerebral involvement.
Because AIDS is the main risk factor for developing severe toxoplasmosis, and toxoplasmic encephalitis is the most common infection for this group, previous genetic studies on Toxoplasma isolates focused only [38 -40] or mainly [41, 42] on patients with AIDS who had toxoplasmic encephalitis, neglecting both patients with toxoplasmosis whose immunosuppression was not due to HIV infection and other clinical presentations of toxoplasmosis. No information about the outcome of the disease was available in these studies. As previously reported in a large study that used a single marker to genotype 71 isolates obtained from immunocompromised patients in France [32] , we confirmed that the distribution of Toxoplasma genotypes (type II vs. non-type II) was not significantly different between patients with AIDS and patients whose immunosuppression was not caused by HIV infection, nor was it significantly different for different sites of infection. Our study provides new data on the distribution of genotypes according to outcome and the geographical origin of toxoplasmic infection in immunocompromised patients. We observed that the distribution of type II and non-type II strains was highly similar for both patients who died of toxoplasmosis and those who survived, leading to the conclusion that the genotype of the strain was probably not a major factor in the outcome. However, the low number of isolates with different genotypes observed among the non-type II strains did not allow analysis of the outcome associated with each of these genotypes. We observed a clear difference in distribution of genotypes, according to the presumed geographical origin of infection. Of 48 patients infected by type II strains, 44 (91.7%) acquired toxoplasmosis in Europe; of 31 patients infected by non-type II strains, 23 (74.2%) acquired toxoplasmosis outside Europe. These results in immunocompromised patients are in accordance with observations regarding the geographical distribution of Toxoplasma genotypes worldwide, which shows an overwhelming predominance of type II strains in France and very likely in other European countries, whatever the host (humans and domestic or wild animals) or the clinical findings (asymptomatic and congenital toxoplasmosis in humans) [24, 26, 27, [43] [44] [45] .
Type II seems endemic only in Europe and North America, and our results confirm the widespread distribution of type III that has already been described in North and South America, Europe, Africa, and Asia [17, 26, 29, 30, 46] . The rarity of type I in our population contrasts with the overrepresentation of this genotype in other studies [38 -42] . This may be explained by true epidemiological differences between our population and the Brazilian population studied by Ferreira et al. [40] or by misidentification of type I in studies that used a single marker [32, 39, 41, 42] . With multilocus typing, conflicting results can be observed when clinical or epidemiological data about the geographical origins of patients are lacking or when the size of clinical samples is too small. For these reasons, it is difficult to know whether type II [17] or type I [38] strains predominate in immunocompromised patients in the United States.
Certain nonarchetypal genotypes were repeatedly recovered from different patients who acquired the infection in subSaharan Africa (genotypes Africa 1 and 2) and in the French West Indies (genotype Caribbean 1). The Africa 1 genotype is the most common in patients who acquired infection in western and central African countries. Since the Africa genotype 1 has been collected in various and distant areas (from Senegal to Uganda) and at different time, this genotype is a candidate for an African clonal lineage. Although recovered from few patients, the Africa 2 and Caribbean 1 genotypes could also be representative of other clonal lineages in Africa and in the Caribbean. Further population genetics analyses with more isolates from different hosts in these areas are needed to confirm these results. These presumed clonal lineages, together with the recovery of 8 unique genotypes from immunocompromised patients, confirm that the genetic diversity of T. gondii is greater than was initially thought. Recent studies in which isolates were collected from chickens in several African countries [28, 29] showed a predominance of archetypal types I, II and III lineages in these areas, which contrasts with the higher proportion of nonarchetypal genotypes (e.g., Africa 1 and 2) recovered from African patients in this study. These differences may suggest a correlation of specific genotypes with clinical toxoplasmosis in immunocompromised patients in Africa, but they must be confirmed by greater sampling of isolates both in patients and animals in Africa.
The influence of the Toxoplasma genotype in human toxoplasmosis remains unclear because other parasite factors (lifecycle stage and inoculum size) and, above all, host factors (immune status and genetic background) play a key role in the natural course of toxoplasmosis [47, 48] . If some data suggest a possible correlation between severe toxoplasmosis and atypical genotypes in immunocompetent patients [1, 2, 49] and in cases of congenital toxoplasmosis [27] , this seems not to be the case in immunocompromised patients who reactivate a type II strain (if acquired in Europe) or a non-type II strain (if acquired in Africa or South America). A larger number of samples are needed to better understand the influence of the different non-type II genotypes in immunocompromised patients. Further investigations that combine parasite genotyping and analysis of host factors, such as cytokine activation and regulation by genes of the major histocompatibility complex [50] , are necessary to better understand host resistance and susceptibility to toxoplasmosis in immunocompromised patients.
